Siltuximab 联合伊达比星和阿糖胞苷化疗在预后不良的急性成髓细胞白血病 (AML) 患者中的剂量递增:SILTUXILAM (SILTUXILAM)
Siltuximab 联合伊达比星和阿糖胞苷化疗在预后不良的急性成髓细胞白血病 (AML) 患者中剂量递增的单中心 1 期研究:SILTUXILAM
This is a phase 1 dose escalation study testing the addition of an anti-IL6 (siltuximab) to standard induction chemotherapy for high-risk AML.
研究概览
详细说明
Administration of siltuximab at day 8 of induction following a classical induction using idarubicin 8mg/m2/d for 5 days and cytarabine 100mg/m2/d for 7 days.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Nantes、法国、44093
- CHU de Nantes
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- age >= 18 years
- AML with a poor prognosis defined according to the criteria below:
LAM First line: Age <60 years and unfavorable risk according to the 2017 ELN Age> = 60 years old and intermediate or unfavorable risk according to the ELN 2017 LAM in Relapse: whatever the age
- ECOG <= 2
- Patient eligible for intensive chemotherapy
- Informed consent
- Liver function tests: transaminases <3x normal, bilirubin <1.5X normal
- Creatinine clearance> 60ml / min
- LVEF> = 50%
Exclusion Criteria:
- Patients with FLT3 ITD or TKD mutation eligible for FLT3 inhibitor therapy
- Uncontrolled infection
- Hep B, C, HIV +
- History of diverticulosis / diverticulitis
- Patients at high risk of gastrointestinal perforation
- No social security or any other scheme
- Pregnant women or patient unable to take contraception (pill, abstinence, IUD not allowed) in case of fertility. contraceptive pill, abstinence, unauthorised IUD) in case of fertility. A patient who cannot continue contraception for at least 3 months after the last SILTUXIMAB injection is not eligible for inclusion.
- Lactating women
- Minors
- Adults under guardianship, curatorship or legal protection
- Hypersensitivity to one of the active substances or to one of the excipients
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:西妥昔单抗
|
Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
分布式账本技术数量
大体时间:45天
|
45天
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluation of the response to induction therapy with idarubicin + cytarabine + siltuximab
大体时间:Day 30 and Day 45
|
Calculation of complete remission (CR) and CR with incomplete recovery (CRi) according to the ELN 2017 definition |
Day 30 and Day 45
|
|
Evaluation of response at D15 after induction
大体时间:Day 15
|
percent bone marrow blasts at D15 (myelogram) |
Day 15
|
|
Assessment of myelotoxicity
大体时间:Day 45
|
Neutrophil recovery time (>1.0 × 109/L) from D1; Platelet recovery time (>100 × 109/L) from D1 |
Day 45
|
|
Overall survival
大体时间:Month 6
|
delay from D1 of induction to date of last news or death |
Month 6
|
|
Leukaemia-free survival
大体时间:Month 6
|
delay between the date of CR and the date of relapse or death or the date of the last follow-up |
Month 6
|
|
Event-free survival
大体时间:Month 6
|
delay between D1 of induction and the date of relapse, death or date of last |
Month 6
|
|
Incidence of relapse if remission
大体时间:Month 6
|
relapse rate at last follow-up |
Month 6
|
|
Infections
大体时间:Month 6
|
monitoring of AEs infection |
Month 6
|
|
Cytokine levels: FLT3L and IL-6
大体时间:Day 1, Day 8, Day 15, Day 22
|
Cytokine levels: FLT3L and IL-6 |
Day 1, Day 8, Day 15, Day 22
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.